INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

NBIXNEUROCRINE BIOSCIENCES INC

CIK 0000914475

EDGAR filingsOpen in network
Disclosed transactions45
Buys / sells0 / 6
Max Insider Score32
Connections13with evidence

NBIX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
3,587 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Connected organizationevidence
    NEUROCRINE BIOSCIENCES PAC INC.FEC Form 1 connected organization: NEUROCRINE BIOSCIENCES, INC. (exact legal-name match) · Nov 4, 2026
  • ← Insider ofevidence
    Cooke JulieChief Human Resources Officer · Sep 15, 2026
  • ← Insider ofevidence
    Abernethy MattChief Financial Officer · Sep 15, 2026
18
BW
Boyer David W.Chief Corp. Affairs Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL
$130K
826 sh
Sep 14, 2026
Sep 15, 2026
traded Sep 14, 2026
+1d
SEC FORM 4

Evidence

9
BW
Boyer David W.Chief Corp. Affairs Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding · 10b5-1 plan
F$302K
1,936 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

13
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
4,483 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

25
AM
Abernethy MattChief Financial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$363K
2,311 sh
Sep 14, 2026Sep 15, 2026
traded Sep 14, 2026
+1dSEC FORM 4

Evidence

15
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$378K
2,419 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

3
BW
Boyer David W.Chief Corp. Affairs Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award · 10b5-1 plan
A—
3,587 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

9
AM
Abernethy MattChief Financial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding · 10b5-1 plan
F$423K
2,709 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

3
AM
Abernethy MattChief Financial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award · 10b5-1 plan
A—
5,020 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

13
CJ
Cooke JulieChief Human Resources Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
3,587 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

19
CJ
Cooke JulieChief Human Resources Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$302K
1,936 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

27
KC
Keswani Sanjay ChandruChief Medical Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$330K
2,112 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

21
KC
Keswani Sanjay ChandruChief Medical Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
3,914 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

15
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$302K
1,936 sh
Sep 11, 2026Sep 15, 2026
traded Sep 11, 2026
+4dSEC FORM 4

Evidence

21
BE
Benevich EricChief Commercial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$333K
2,154 sh
Sep 9, 2026Sep 10, 2026
traded Sep 9, 2026
+1dSEC FORM 4

Evidence

0
BE
Benevich EricChief Commercial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise · 10b5-1 plan
M—
3,194 sh
Sep 9, 2026Sep 10, 2026
traded Sep 9, 2026
+1dSEC FORM 4

Evidence

6
BE
Benevich EricChief Commercial Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise · 10b5-1 plan
M$138K
3,194 sh
Sep 9, 2026Sep 10, 2026
traded Sep 9, 2026
+1dSEC FORM 4

Evidence

12
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Gift
G—
2,441 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

9
KC
Keswani Sanjay ChandruChief Medical Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
3,212 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

15
KC
Keswani Sanjay ChandruChief Medical Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$268K
1,733 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

21
KC
Keswani Sanjay ChandruChief Medical Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
3,212 sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

0
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise · 10b5-1 plan
M—
2,261 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

25
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$354K
2,261 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

6
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise · 10b5-1 plan
M$179K
2,261 sh
May 29, 2026Jun 2, 2026
traded May 29, 2026
+4dSEC FORM 4

Evidence

13
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise · 10b5-1 plan
M$932K
11.0K sh
May 27, 2026May 29, 2026
traded May 27, 2026
+2dSEC FORM 4

Evidence

32
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$1.71M
11.0K sh
May 27, 2026May 29, 2026
traded May 27, 2026
+2dSEC FORM 4

Evidence

11
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise · 10b5-1 plan
M—
11.0K sh
May 27, 2026May 29, 2026
traded May 27, 2026
+2dSEC FORM 4

Evidence

9
MJ
Mercier JohannaDirector
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
2,567 sh
May 27, 2026May 29, 2026
traded May 27, 2026
+2dSEC FORM 4

Evidence

29
BW
Boyer David W.Chief Corp. Affairs Officer
NBIXNEUROCRINE BIOSCIENCES INC
Open-market sale · 10b5-1 plan
SELL$609K
3,888 sh
May 26, 2026May 28, 2026
traded May 26, 2026
+2dSEC FORM 4

Evidence

9
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
5,479 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

9
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
1,359 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

21
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
1,401 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

23
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
1,600 sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

30
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$1.33M
10.8K sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

21
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
19.9K sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

16
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$91K
734 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

17
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
1,359 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

16
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$94K
756 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

17
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
1,401 sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

22
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$108K
881 sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

23
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
1,600 sh
Feb 12, 2026Feb 17, 2026
traded Feb 12, 2026
+5dSEC FORM 4

Evidence

9
DI
Delaet IngridChief Regulatory Officer
NBIXNEUROCRINE BIOSCIENCES INC
Grant or award
A—
31.2K sh
Feb 13, 2026Feb 17, 2026
traded Feb 13, 2026
+4dSEC FORM 4

Evidence

17
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
4,426 sh
Nov 29, 2025Dec 2, 2025
traded Nov 29, 2025
+3dSEC FORM 4

Evidence

9
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Option exercise
M—
4,426 sh
Nov 29, 2025Dec 2, 2025
traded Nov 29, 2025
+3dSEC FORM 4

Evidence

19
OJ
Onyia JudeChief Scientific Officer
NBIXNEUROCRINE BIOSCIENCES INC
Tax withholding
F$342K
2,248 sh
Nov 29, 2025Dec 2, 2025
traded Nov 29, 2025
+3dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Benevich EricChief Commercial Officer · Sep 10, 2026
  • ← Lobbied forevidence
    BGR GOVERNMENT AFFAIRSLDA Q2 2026 second quarter · Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    CAPITOL COUNSEL LLCLDA Q1 2026 first quarter · Budget/appropriations, Health issues, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    TARPLIN, DOWNS & YOUNG, LLCLDA Q1 2026 first quarter · Health issues, Medicare/Medicaid, Budget/appropriations · Aug 26, 2026
  • ← Insider ofevidence
    Keswani Sanjay ChandruChief Medical Officer · Jun 4, 2026
  • ← Insider ofevidence
    Mercier JohannaDirector · May 29, 2026
  • ← Insider ofevidence
    Boyer David W.Chief Corp. Affairs Officer · May 28, 2026
  • ← Insider ofevidence
    Delaet IngridChief Regulatory Officer · Feb 17, 2026
  • ← Insider ofevidence
    Onyia JudeChief Scientific Officer · Dec 2, 2025

    • Lobbying

    $1.88M reported · de-duplicated
    2026 Q2 $940K in-house2026 Q1 $940K in-house
    • TARPLIN, DOWNS & YOUNG, LLC$110K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Budget/appropriations
    • BGR GOVERNMENT AFFAIRS$60K2026 Q1 · posted Aug 26, 2026 · Pharmacy
    • CAPITOL COUNSEL LLC$60K2026 Q2 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid
    • TARPLIN, DOWNS & YOUNG, LLC$80K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Budget/appropriations
    • In-house report$940K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues, Budget/appropriations, Taxation
    • BGR GOVERNMENT AFFAIRS—2026 Q1 · posted Aug 26, 2026 · Pharmacy
    • CAPITOL COUNSEL LLC$60K2026 Q1 · posted Aug 26, 2026 · Budget/appropriations, Health issues, Medicare/Medicaid
    • BGR GOVERNMENT AFFAIRS$60K2026 Q2 · posted Aug 26, 2026 · Pharmacy
    • In-house report$940K2026 Q1 · posted Aug 26, 2026 · Taxation, Medicare/Medicaid, Health issues, Budget/appropriations

    Connected PAC contributions

    FEC · direct to members
    • Scott H. PetersD$7,000NEUROCRINE BIOSCIENCES PAC INC.
    • Aaron BeanR$5,000NEUROCRINE BIOSCIENCES PAC INC.
    • Juan CiscomaniR$5,000NEUROCRINE BIOSCIENCES PAC INC.
    • Kevin MullinD$4,500NEUROCRINE BIOSCIENCES PAC INC.
    • Thomas H. Kean, Jr.R$3,500NEUROCRINE BIOSCIENCES PAC INC.
    Robin L. KellyD
    $3,500
    NEUROCRINE BIOSCIENCES PAC INC.
  • Brian K. FitzpatrickR$3,500NEUROCRINE BIOSCIENCES PAC INC.
  • Vern BuchananR$3,500NEUROCRINE BIOSCIENCES PAC INC.
  • Roger MarshallR$3,500NEUROCRINE BIOSCIENCES PAC INC.
  • Shelley Moore CapitoR$3,500NEUROCRINE BIOSCIENCES PAC INC.
  • Gus M. BilirakisR$3,000NEUROCRINE BIOSCIENCES PAC INC.
  • John R. CurtisR$3,000NEUROCRINE BIOSCIENCES PAC INC.